118 related articles for article (PubMed ID: 7699623)
1. Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares.
Walz LeBlanc BA; Gladman DD; Urowitz MB
J Rheumatol; 1994 Dec; 21(12):2239-41. PubMed ID: 7699623
[TBL] [Abstract][Full Text] [Related]
2. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
Ng KP; Manson JJ; Rahman A; Isenberg DA
Arthritis Rheum; 2006 Dec; 55(6):900-4. PubMed ID: 17139667
[TBL] [Abstract][Full Text] [Related]
3. Clinically active serologically quiescent systemic lupus erythematosus.
Gladman DD; Hirani N; Ibañez D; Urowitz MB
J Rheumatol; 2003 Sep; 30(9):1960-2. PubMed ID: 12966598
[TBL] [Abstract][Full Text] [Related]
4. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome.
Steiman AJ; Gladman DD; Ibañez D; Urowitz MB
J Rheumatol; 2010 Sep; 37(9):1822-7. PubMed ID: 20595281
[TBL] [Abstract][Full Text] [Related]
5. Prolonged remission in systemic lupus erythematosus.
Urowitz MB; Feletar M; Bruce IN; Ibañez D; Gladman DD
J Rheumatol; 2005 Aug; 32(8):1467-72. PubMed ID: 16078321
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.
Steiman AJ; Gladman DD; Ibañez D; Urowitz MB
Arthritis Care Res (Hoboken); 2012 Apr; 64(4):511-8. PubMed ID: 22162433
[TBL] [Abstract][Full Text] [Related]
7. Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
Steiman AJ; Gladman DD; Ibañez D; Noamani B; Landolt-Marticorena C; Urowitz MB; Wither JE
J Rheumatol; 2015 Dec; 42(12):2318-26. PubMed ID: 26568589
[TBL] [Abstract][Full Text] [Related]
8. Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
Steiman AJ; Urowitz MB; Ibañez D; Li TT; Gladman DD; Wither J
J Rheumatol; 2015 May; 42(5):810-6. PubMed ID: 25729033
[TBL] [Abstract][Full Text] [Related]
9. Follow-up and management of serologically active clinically quiescent cases in pediatric systemic lupus erythematosus.
Capone G; Lojacono C; Al-Bayitee F; Makvandi S; Hennon T; Wrotniak B; Abdul-Aziz R
Reumatologia; 2021; 59(4):244-251. PubMed ID: 34538955
[TBL] [Abstract][Full Text] [Related]
10. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
Conti F; Ceccarelli F; Perricone C; Miranda F; Truglia S; Massaro L; Pacucci VA; Conti V; Bartosiewicz I; Spinelli FR; Alessandri C; Valesini G
PLoS One; 2012; 7(9):e45934. PubMed ID: 23029327
[TBL] [Abstract][Full Text] [Related]
11. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus.
Nikpour M; Urowitz MB; Ibañez D; Gladman DD
Arthritis Rheum; 2009 Sep; 61(9):1152-8. PubMed ID: 19714602
[TBL] [Abstract][Full Text] [Related]
12. Correlation between clinical activity and serological markers in a wide cohort of patients with systemic lupus erythematosus: an eight-year prospective study.
Villegas-Zambrano N; Martínez-Taboada VM; Bolívar A; San Martín M; Alvarez L; Marín MJ; López-Hoyos M
Ann N Y Acad Sci; 2009 Sep; 1173():60-6. PubMed ID: 19758133
[TBL] [Abstract][Full Text] [Related]
13. Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study.
Huang H; Mu L; Zhang Z; Gao D; Hao Y; Zhou W
Arthritis Res Ther; 2021 Oct; 23(1):275. PubMed ID: 34715915
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study.
Petri M; Singh S; Tesfasyone H; Malik A
J Rheumatol; 2009 Nov; 36(11):2476-80. PubMed ID: 19833757
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with active systemic lupus erythematosus after endstage renal disease.
Szeto CC; Li PK; Wong TY; Leung CB; Lui SF
J Rheumatol; 1998 Aug; 25(8):1520-5. PubMed ID: 9712094
[TBL] [Abstract][Full Text] [Related]
16. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population.
Jonsson H; Nived O; Sturfelt G
Medicine (Baltimore); 1989 May; 68(3):141-50. PubMed ID: 2785628
[TBL] [Abstract][Full Text] [Related]
17. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study.
Zonana-Nacach A; Salas M; Sánchez ML; Camargo-Coronel A; Bravo-Gatica C; Mintz G
J Rheumatol; 1995 Jan; 22(1):45-9. PubMed ID: 7699680
[TBL] [Abstract][Full Text] [Related]
18. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.
Mikdashi J; Handwerger B
Rheumatology (Oxford); 2004 Dec; 43(12):1555-60. PubMed ID: 15342927
[TBL] [Abstract][Full Text] [Related]
19. Serum complement determinations in patients with quiescent systemic lupus erythematosus.
Sullivan KE; Wisnieski JJ; Winkelstein JA; Louie J; Sachs E; Choi R; Veksler E; Goldman D; Petri M
J Rheumatol; 1996 Dec; 23(12):2063-7. PubMed ID: 8970042
[TBL] [Abstract][Full Text] [Related]
20. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
Inês L; Duarte C; Silva RS; Teixeira AS; Fonseca FP; da Silva JA
Rheumatology (Oxford); 2014 Jan; 53(1):85-9. PubMed ID: 24067885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
